Literature DB >> 17001160

A working group classification of focal prostate atrophy lesions.

Angelo M De Marzo1, Elizabeth A Platz, Jonathan I Epstein, Tehmina Ali, Anthanase Billis, Teresa Y Chan, Liang Cheng, Milton Datta, Lars Egevad, Dilek Ertoy-Baydar, Xavier Farre, Xavier Farree, Samson W Fine, Kenneth A Iczkowski, Michael Ittmann, Beatrice S Knudsen, Massimo Loda, Antonio Lopez-Beltran, Cristina Magi-Galluzzi, Gregor Mikuz, Roldolfo Montironi, Eli Pikarsky, Galina Pizov, Mark A Rubin, Hema Samaratunga, Thomas Sebo, Isabel A Sesterhenn, Rajal B Shah, Rajiv B Shah, Sabina Signoretti, Jeffery Simko, George Thomas, Patricia Troncoso, Toyonori T Tsuzuki, Geert J van Leenders, Ximing J Yang, Ming Zhou, William D Figg, Ashraful Hoque, Ashrafal Hoque, M S Lucia.   

Abstract

Focal atrophy is extremely common in prostate specimens. Although there are distinct histologic variants, the terminology is currently nonstandardized and no formal classification has been tested for interobserver reliability. This lack of standardization hampers the ability to study the biologic and clinical significance of these lesions. After informal and formal meetings by a number of the authors, focal atrophy lesions were categorized into 4 distinct subtypes as follows: (i) simple atrophy, (ii) simple atrophy with cyst formation, (iii) postatrophic hyperplasia, and (iv) partial atrophy. In phase 1 of the study, pathologists with varying levels of experience in prostate pathology were invited to view via the Internet a set of "training" images with associated descriptions of lesions considered typical of each subtype. In phase 2 of the study, each participant provided diagnoses on a series of 140 distinct "test" images that were viewed over the Internet. These test images consisted of the 4 subtypes of atrophy and images of normal epithelium, high grade prostatic intraepithelial neoplasia, and carcinoma. The diagnoses for each image from each pathologist were compared with a set of "standard" diagnoses and the kappa statistic was computed. Thirty-four pathologists completed both phases of the study. The interobserver reliability (median kappa) for classification of lesions as normal, cancer, prostatic intraepithelial neoplasia, or focal atrophy was 0.97. The median kappa for the classification of atrophy lesions into the 4 subtypes was 0.80. The median percent agreement with the standard diagnosis for the atrophy subtypes were: simple 60.6%, simple with cyst formation 100%; postatrophic hyperplasia 87.5%; partial atrophy 93.9%. The lower percentage for simple atrophy reflected a propensity to diagnose some of these as simple atrophy with cyst formation. Seven pathologists completed the phase 2 analysis a second time, and their intraobserver reproducibility was excellent. Three of 4 pathologists with low agreement with the standard diagnosis for simple atrophy improved their scores after repeating the analysis after re-examination of the "training set" of images. In conclusion, these criteria for variants of focal prostate atrophy may facilitate studies to examine the relation between various patterns of prostate atrophy and prostate cancer.

Entities:  

Mesh:

Year:  2006        PMID: 17001160     DOI: 10.1097/01.pas.0000213289.50660.be

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  26 in total

1.  [Prostate biopsy - an unending story].

Authors:  G Mikuz
Journal:  Pathologe       Date:  2012-03       Impact factor: 1.011

2.  Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer.

Authors:  Sabina Davidsson; Michelangelo Fiorentino; Ove Andrén; Fang Fang; Lorelei A Mucci; Eberhard Varenhorst; Katja Fall; Jennifer R Rider
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-27       Impact factor: 4.254

3.  Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer.

Authors:  Francesca Giunchi; Kristina Jordahl; Enrico Bollito; Maurizio Colecchia; Carlo Patriarca; Antonietta D'Errico; Francesco Vasuri; Deborah Malvi; Alessandro Fornari; Luca Reggiani Bonetti; Barbara Corti; Mauro Papotti; Paolo DeGiuli; Massimo Loda; Rodolfo Montironi; Michelangelo Fiorentino; Jennifer R Rider
Journal:  Virchows Arch       Date:  2017-04-12       Impact factor: 4.064

Review 4.  [Non-neoplastic alterations of the prostate. Why should pathologists know them?].

Authors:  A Erbersdobler
Journal:  Pathologe       Date:  2013-09       Impact factor: 1.011

Review 5.  The diet as a cause of human prostate cancer.

Authors:  William G Nelson; Angelo M Demarzo; Srinivasan Yegnasubramanian
Journal:  Cancer Treat Res       Date:  2014

6.  A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer.

Authors:  Yiwen Zhang; Cindy Ke Zhou; Michelangelo Fiorentino; Ericka M Ebot; Emily M Rencsok; Katja Fall; Tamara L Lotan; Massimo Loda; Francesca Giunchi; Elizabeth A Platz; Angelo M De Marzo; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-09-18       Impact factor: 4.254

Review 7.  The benign mimickers of prostatic acinar adenocarcinoma.

Authors:  Yuqiao Xu; Yingmei Wang; Ru Zhou; Haiyang Li; Hong Cheng; Zhe Wang; Jing Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

Review 8.  ETS rearrangements in prostate cancer.

Authors:  Mark A Rubin
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

9.  A Phase II Randomized Trial of Lycopene-Rich Tomato Extract Among Men with High-Grade Prostatic Intraepithelial Neoplasia.

Authors:  Peter H Gann; Ryan J Deaton; Erika Enk Rueter; Richard B van Breemen; Larisa Nonn; Virgilia Macias; Misop Han; Viju Ananthanarayanan
Journal:  Nutr Cancer       Date:  2015       Impact factor: 2.900

Review 10.  Anti-inflammatory drugs, antioxidants, and prostate cancer prevention.

Authors:  Aditya Bardia; Elizabeth A Platz; Srinivasan Yegnasubramanian; Angelo M De Marzo; William G Nelson
Journal:  Curr Opin Pharmacol       Date:  2009-07-01       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.